This next generation CD38-targeting molecule potently induces a cytotoxic T cell response to kill MM cells via cytolytic cytokine production (i.e., interferon-gamma (IFNγ), granzyme B (GZMB), perforin (PRF1)), with minimal toxicity on T effector cells. The gene discussed is PRF1; the disease is Miyoshi myopathy.